86 related articles for article (PubMed ID: 8910856)
1. Screening for cytochrome P450 3A in man: studies with midazolam and nifedipine.
Yeates RA; Scharpf F; Laufen H; Zimmermann T
J Pharm Pharmacol; 1996 Sep; 48(9):933-4. PubMed ID: 8910856
[TBL] [Abstract][Full Text] [Related]
2. Alteration of drug-metabolizing enzyme activity in palliative care patients: Microdosed assessment of cytochrome P450 3A.
Geist M; Bardenheuer H; Burhenne J; Mikus G
Palliat Med; 2019 Jul; 33(7):850-855. PubMed ID: 31023150
[TBL] [Abstract][Full Text] [Related]
3. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
4. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
[TBL] [Abstract][Full Text] [Related]
5. Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions.
Wilkinson GR
Clin Pharmacol Ther; 2004 Aug; 76(2):99-103. PubMed ID: 15289786
[No Abstract] [Full Text] [Related]
6. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity.
Kurnik D; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2006 Sep; 80(3):228-34. PubMed ID: 16952489
[TBL] [Abstract][Full Text] [Related]
7. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Greenblatt DJ; von Moltke LL; Harmatz JS; Chen G; Weemhoff JL; Jen C; Kelley CJ; LeDuc BW; Zinny MA
Clin Pharmacol Ther; 2003 Aug; 74(2):121-9. PubMed ID: 12891222
[TBL] [Abstract][Full Text] [Related]
8. Role of small intestinal cytochromes p450 in the bioavailability of oral nifedipine.
Zhang QY; Kaminsky LS; Dunbar D; Zhang J; Ding X
Drug Metab Dispos; 2007 Sep; 35(9):1617-23. PubMed ID: 17567730
[TBL] [Abstract][Full Text] [Related]
9. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
10. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
Uehara S; Uno Y; Nakanishi K; Ishii S; Inoue T; Sasaki E; Yamazaki H
Drug Metab Dispos; 2017 May; 45(5):457-467. PubMed ID: 28196829
[TBL] [Abstract][Full Text] [Related]
11. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
12. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats.
Choi JS; Choi I; Choi DH
Eur J Drug Metab Pharmacokinet; 2016 Jun; 41(3):231-8. PubMed ID: 25549928
[TBL] [Abstract][Full Text] [Related]
14. Gas chromatographic determination of nisoldipine and one of its metabolites in plasma.
Van Harten J; Lodewijks MT; Guyt-Scholten JW; Van Brummelen P; Breimer DD
J Chromatogr; 1987 Dec; 423():327-33. PubMed ID: 3443667
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic interactions of nifedipine and quinidine.
Hippius M; Henschel L; Sigusch H; Tepper J; Brendel E; Hoffmann A
Pharmazie; 1995 Sep; 50(9):613-6. PubMed ID: 7480098
[TBL] [Abstract][Full Text] [Related]
16. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting.
Ahonen J; Olkkola KT; Salmenperä M; Hynynen M; Neuvonen PJ
Anesthesiology; 1996 Dec; 85(6):1246-52. PubMed ID: 8968170
[TBL] [Abstract][Full Text] [Related]
17. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.
Zhou XJ; Zhou-Pan XR; Gauthier T; Placidi M; Maurel P; Rahmani R
Biochem Pharmacol; 1993 Feb; 45(4):853-61. PubMed ID: 8452560
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
[TBL] [Abstract][Full Text] [Related]
19. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
[TBL] [Abstract][Full Text] [Related]
20. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
